Aciclovir (BW 248U)

Catalog No.S1807 Synonyms: Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011

For research use only.

Acyclovir (BW 248U, Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

Aciclovir (BW 248U) Chemical Structure

CAS No. 59277-89-3

Selleck's Aciclovir (BW 248U) has been cited by 13 publications

Purity & Quality Control

Choose Selective Antiviral Inhibitors

Biological Activity

Description Acyclovir (BW 248U, Acyclovir, Acycloguanosine, Zovirax, ACV, NSC 645011) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.
Targets
HSV [1]
In vitro

Acyclovir sensitivity of herpes simplex virus isolates is determined in a plaque-reduction assay in Vero cells. IC50 Values are consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains are 2-10-fold less sensitive than Type 1 strains[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BSC-1 cells M{fmemZ2dmO2aX;uJIF{e2G7 M1vYbWFvfGm4aYLhcEBi[3Srdnn0fUBw\iC2aHWgZ49ueG:3bnSge4F{KGW4YXz1ZZRm\CCjZ3HpcpN1KHSqZTDI[ZJx\XNic3ntdIxmgCC4aYL1d{B1gXCnLUGgbY4hSlOFLUGgZ4VtdHNuIFnDOVA:Oi54IN88US=> NIL2VVAzQTF|M{Cw
P3HR-1 cells MWrGeY5kfGmxbjDhd5NigQ>? NXjGdHpnTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36g[o9zKHSqZTDpcohq[mm2aX;uJI9nKEWyc4TlbY4uSmG{cjD2bZJ2eyCHQm[tSG5CKHO7boTo[ZNqeyCrbjDoeY1idiCueX3wbI9jdGG|dH;p[EBRO0iULUGgZ4VtdHNuIFXDOVA:Pi55NTFOwG0> NV;nc3pPOTJ2MEi3NlY>
HFF cells MUPGeY5kfGmxbjDhd5NigQ>? NYPsVlBqS2:wY3XueJJifGmxbjDmc5IhUFOYLUGgdIxieXWnIILl[JVkfGmxbjCoWnBTMSCkeTC1NEUhcW5iSF\GJINmdGy|LDDFR|UxRTFwMTFOwG0> MlXRNVQ2QDR7NUS=
HFF cells MYnGeY5kfGmxbjDhd5NigQ>? NEDKbWdKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hemWmdXPlJGhUXi1zIHnu[JVk\WRiY4n0c5BifGixZ3XubYMh\W[oZXP0JEhEWEVrIHL5JFUxKCViaX6gTGZHKGOnbHzzMEBGSzVyPUKuNlIh|ryP M3zY[lE1PTh2OUW0
human embryonic lung cells M{D4PWZ2dmO2aX;uJIF{e2G7 M2O4WWFvfGm4aYLhcEBi[3Srdnn0fUB4[XNibXXhd5Vz\WRiYYOg[YZn\WO2aY\lJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gdoVlfWOnIG\hdolk\WyuYTDac5N1\XJidnnyeZMhME:NQTmtbY5lfWOnZDDwcIFyfWViZn;ycYF1cW:wIHnuJIh2dWGwIHXtZpJ6d26rYzDseY5oKGOnbHzzMEBGSzVyPUGuNUDPxE1? NF[wSpMyOTV2OUS1Oy=>
HEL cells MYrGeY5kfGmxbjDhd5NigQ>? NG\5NIpEd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDhcpRqNX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHNXNTFqRzmgbY4hUEWOIHPlcIx{NCCHQ{WwQVEvOyEQvF2= NVP5TpluOTR4NEOzNlg>
HEL cell MWPGeY5kfGmxbjDhd5NigQ>? MYXF[oZm[3SrdnWgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IGT5do9{cW6nIHvpcoF{\SBqVFurLUBX[XKrY3XscIEuYm:|dHXyJJZqenW|LXnu[JVk\WRiY4n0c5BifGirY3n0fUBjgSB3MDWgbY4hV0uDIIP0doFqdiCKRVygZ4VtdCCuaX7ld{whTUN3ME20MlU{KM7:TR?= MVmxNVQ6PTV6Nh?=
HSV-2 MS Vero cells NXjiU202TnWwY4Tpc44h[XO|YYm= Ml7jTY5pcWKrdHnvckBw\iC4aYLhcEBkgXSxcHH0bIlkKGWoZnXjeEBqdiCrbn\lZ5Rm\CCqdX3hckBnd3Knc3vpckBncWK{b3LsZZN1KGOnbHygcY9vd2yjeXXyd{Bw\iCKU2[tNkBOWyCYZYLvJINmdGy|IHL5JFUxLSxiRVO1NF03NjJizszN M3rTTlEyPTh3NEW3
HSV-1 E-377 Vero cells MXXGeY5kfGmxbjDhd5NigQ>? NYfhfHJNUW6qaXLpeIlwdiCxZjDwcIFyfWViZn;ycYF1cW:wIHnuJI1wdm:uYYnldpMhd2ZiSGPWMVEhTS1|N{egWoVzdyClZXzsd{BjgSB3MDWsJGVEPTB;ND60JO69VQ>? MnvHNVE2QDV2NUe=
HSV-1 KOS Vero cells NEm0UGxHfW6ldHnvckBie3OjeR?= M{f6VmlvcGmkaYTpc44hd2ZicHzhdZVmKG[xcn3heIlwdiCrbjDtc45wdGG7ZYLzJI9nKEiVVj2xJGtQWyCYZYLvJINmdGy|IHL5JFUxLSxiRVO1NF0zNjJizszN NGX2cmEyOTV6NUS1Oy=>
HeLa cell Mk\ESpVv[3Srb36gZZN{[Xl? Mn\IRYJqdGm2eTD0c{BqdmirYnn0JIN6fG:yYYToc4dmdmmlaYT5JI9nKGincoDld{B{cW2ybHX4JJR6eGViMTD2bZJ2eyBqRzmgbY4hUGWOYTDj[YxtKGO3bIT1doUtKEmFNUC9NE4yQSEQvF2= Mn;ENVE{PTZzMUC=
HEp-2 cells MknkSpVv[3Srb36gZZN{[Xl? NVTzPFI5VWmwaX31cUBqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZ4F2e2mwZzCyOUUhcW6qaXLpeIlwdiCxZjDjfZRweGG2aHnjJIVn\mWldDDpcoR2[2WmIHL5JGhmenCnczDzbY1xdGW6II\pdpV{NTFiKFu5O|kqKGmwIFjFdE0zKGOnbHzz NES3UJAzQDR{NUC2
HeLa cells M3\RPGZ2dmO2aX;uJIF{e2G7 M2Hlc2lvcGmkaYTpc44hd2ZiSGPWMVEhTE6DIIP5cpRp\XOrczDpckB3cXK3cz3pcoZm[3SnZDDI[WxiKGOnbHzzMEBKSzVyPUGuPUDPxE1? NGPBXZg4PzV{MkC2
human HFF cells MmjmSpVv[3Srb36gZZN{[Xl? M1i1U2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDv[kB1cGViZIL1[{Bi\2GrboP0JJRp\SCleYTvdIF1cGmlIHXm[oVkfCCob4KgSU0{Pzdic4TyZYlvKG:oIHjldpBmeyC|aX3wcIV5KH[rcoXzMVEhMEiVVj2xLUBqdiCqdX3hckBJTkZiY3XscJMtKEWFNUC9NE4xPCEQvF2= Mk\NPFM6PDl|Mx?=
human HFF cells NX\IT5BHTnWwY4Tpc44h[XO|YYm= MV\Jcohq[mm2b4L5JINwdmOnboTyZZRqd25ib3[geIhmKGS{dXegZYdicW6|dDD0bIUh[3m2b4DheIhq[yCnZn\lZ5Qh\m:{IF3TJJN1emGrbjDv[kBp\XKyZYOgd4lueGyneDD2bZJ2ey1{IDjIV3YuOiliaX6gbJVu[W5iSF\GJINmdGy|LDDFR|UxRTBwMEmg{txO NXn2dHJXQDN7NEmzNy=>
MRC-5 cells MmLuSpVv[3Srb36gZZN{[Xl? M4HVWWFvfGm4aYLhcEBi[3Srdnn0fUBqdiCybHHxeYUhemWmdXP0bY9vKGG|c3H5JJdieyCmZYTldo1qdmWmIHHnZYlve3RiaHXydIV{KHOrbYDs[Zghfmm{dYOgeJlx\SB{IDjIV3YuOiliaX6gUXJENTViY3XscJMtKEmFNUC9Nk42KM7:TR?= NW\JcJZyOjF3M{KwNi=>
human lung fibroblasts (MRC-5) MkSxSpVv[3Srb36gZZN{[Xl? NYDsWmQ1S2:vcH;1coQhf2G|IITld5Rm\CCob4KgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVzeGW|IGPpcZBt\XhidnnyeZMhXHmyZT2xLFE5OTh7KTDpckBpfW2jbjDseY5oKG[rYoLvZoxie3S|IDjNVmMuPSl? NH\YXGs{ODRyOUm4
Raji cells Mn3LSpVv[3Srb36gZZN{[Xl? M3[2TGlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDv[kB1cGViZIL1[{Bi\2GrboP0JJRp\SCjboTp[4VvKHC{b3T1Z5Rqd25iYXfhbY5{fCCSM1jSMVEhe3S{YXnuJI9nKGWyc4TlbY4h[mG{cjD2bZJ2ey1{IDjFRnYqKGmwIGLhbokh[2WubIOsJGVEPTB;Mj65JO69VQ>? NFXoTWE5Ozl2OUOz
Vero cells NVLSbnd7TnWwY4Tpc44h[XO|YYm= MoPsTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JIhmenCnczDzbY1xdGW6II\pdpV{KHS7cHWgNkApUFOYIEKpJJN1emGrbjCxPFYhcW5iVnXyc{Bk\WyuczygTWM2OD1zLkeg{txO MnTjPFU4Pjl{Mh?=
BSC-1 cells M2TIcWZ2dmO2aX;uJIF{e2G7 MX\F[oZm[3SrdnWgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHjldpBmeyC|aX3wcIV5KH[rcoXzJFEhcW5iQmPDMVEh[2WubIOgbY4hTUyLU1GsJGVEPTB;MT61JO69VQ>? NWPpUG5qOTV4M{SwNFM>
HFF cells NEXYNnhHfW6ldHnvckBie3OjeR?= M2PKdWVn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgeoFzcWOnbHzhJJpwe3SncjD2bZJ2eyC{ZYDsbYNifGmxbjDpckBJTkZiY3XscJMtKEWFNUC9NU43KM7:TR?= NEPkNoQyPTZ|NECwNy=>
HFF cells Ml7ISpVv[3Srb36gZZN{[Xl? MVnF[oZm[3SrdnWgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHjldpBmeyC|aX3wcIV5KH[rcoXzJFEhcW5iSF\GJINmdGy|IHnuJIN6fG:yYYTobYMh\W[oZXP0JEhEWEVrIHHzd4F6NCCHQ{WwQVAvQSEQvF2= NI\RPFgyPTZ|NECwNy=>
Daudi cells MoXzSpVv[3Srb36gZZN{[Xl? M1rqb2lvcGmkaYTpc44hd2ZiRVLWJJJmeGyrY3H0bY9vKGmwIFTheYRqKGOnbHzzJIJ6KH[rcnHsJINieHOrZDDhcpRq\2WwLVXMTXNCNCCHQ{WwQVAvOzNizszN MX2xO|AxPDd{Nh?=
african green monkey Vero cells NITv[I5HfW6ldHnvckBie3OjeR?= NGLEdnM1QCCq M2D2[WFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhUXjJic4TyZYlvKDN|MzDpcoZm[3SnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY4n0c5BifGirYzDl[oZm[3RiYX\0[ZIhPDhiaILzJIJ6KHCuYYH1[UBz\WS3Y4Tpc44h[XO|YYmsJGVEPTB;MT64O{DPxE1? M1\ENVIzPzB2OEmw
WI-38 cell NGTYWJFHfW6ldHnvckBie3OjeR?= MYXBcpRqKH[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnpXMHCybHzhJJN1emGrbjmgbY4hX0lvM{igZ4VtdCCvb37vcIF6\XK|LDDJSFUxRTRizszN M{fLbFE{OTZ7Nk[=
HEL cells NWjqNnhrTnWwY4Tpc44h[XO|YYm= NVexbGlxPCCmYYnz NXrEeZlySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUFOYMTDLU3MhcW6oZXP0[YQhcW5iSFXMJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bI9o\W6rY3n0fUBi\nSncjC0JIRigXNuIFXDOVA:OC5{IN88US=> NH;HNGgzOjR3OUi3Oi=>
HEL cells NUS0e|hsTnWwY4Tpc44h[XO|YYm= Mn7TRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTHNXOSCNT2OgbY5n\WO2ZXSgbY4hUEWOIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDygSWM2OD1yLkG0JO69VQ>? NWnPRYxnOjNyOUmwPVc>
African green monkey Vero 76 cells M4LaT2N6fG:2b4jpZ4l1gSCjc4PhfS=> M{nTcFQ5NTl4IHi= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJFc3KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JJRwKDl4IHjyd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whS0N3ME2xN{DPxE1? MoXNNlYyOTl7OUK=
In vivo low-dose oral acyclovir may be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections[3].

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 45 mg/mL
(199.82 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 225.2
Formula

C8H11N5O3

CAS No. 59277-89-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC2=C(N1COCCO)N=C(NC2=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04448392 Recruiting Drug: Valacyclovir Neonatal Herpes Simplex Infection University of Alabama at Birmingham July 1 2021 Phase 1
NCT02997982 Completed Drug: Valaciclovir 500Mg Tablet Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex Hugo Lovheim|Umeå University December 2016 Phase 2
NCT02879630 Recruiting -- Obesity West Virginia University August 2016 --
NCT02152358 Unknown status Drug: Aciclovir|Drug: Ganciclovir|Drug: Placebo Viral Pneumonia Assistance Publique Hopitaux De Marseille March 2014 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aciclovir (BW 248U) | Aciclovir (BW 248U) ic50 | Aciclovir (BW 248U) price | Aciclovir (BW 248U) cost | Aciclovir (BW 248U) solubility dmso | Aciclovir (BW 248U) purchase | Aciclovir (BW 248U) manufacturer | Aciclovir (BW 248U) research buy | Aciclovir (BW 248U) order | Aciclovir (BW 248U) mouse | Aciclovir (BW 248U) chemical structure | Aciclovir (BW 248U) mw | Aciclovir (BW 248U) molecular weight | Aciclovir (BW 248U) datasheet | Aciclovir (BW 248U) supplier | Aciclovir (BW 248U) in vitro | Aciclovir (BW 248U) cell line | Aciclovir (BW 248U) concentration | Aciclovir (BW 248U) nmr